SclerFIX-IP

Phase 2Biologic

TTBF Genie Tissulaire

SclerFIX-IP is one of 5 biologic programs targeting Osteoarthritis, Hand. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteoarthritis, HandTerminated

Osteoarthritis, HandPhase 2

Terminated

Competition

Competitive Landscape

4 competitors in Osteoarthritis, Hand

#DrugCompanyPhaseTrials

Voltaren

Glucophage

Activella

Voltaren

SclerFIX-IP

TTBF Genie Tissulaire

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis, Hand2 trials

Evaluation of the Treatment of Symptomatic Scaphotrapeziotrapezoidal (STT) Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition

Active, not recruiting·TTBF Genie Tissulaire·Phase 2·NCT06038331·14 enrolled

Evaluation of the Treatment of Symptomatic Proximal InterPhalangeal (PIP) Joint Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition

Terminated·TTBF Genie Tissulaire·Phase 2·NCT06034262·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SclerFIX-IP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SclerFIX-IP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SclerFIX-IP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TBF Genie Tissulaire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TTBF Genie Tissulaire

SclerFIX-IP

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis, Hand2 trials

References

Drug Info

Quick Facts

Related News